347 related articles for article (PubMed ID: 36058945)
21. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
22. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
23. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.
Galon J; Fox BA; Bifulco CB; Masucci G; Rau T; Botti G; Marincola FM; Ciliberto G; Pages F; Ascierto PA; Capone M
J Transl Med; 2016 Sep; 14():273. PubMed ID: 27650038
[TBL] [Abstract][Full Text] [Related]
24. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.
Ascierto PA; Warner AB; Blank C; Caracò C; Demaria S; Gershenwald JE; Khushalani NI; Long GV; Luke JJ; Mehnert JM; Robert C; Rutkowski P; Tawbi HA; Osman I; Puzanov I
J Transl Med; 2022 May; 20(1):200. PubMed ID: 35538491
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
26. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
Flynn MJ; Larkin JMG
Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
[TBL] [Abstract][Full Text] [Related]
27. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.
da Silveira Nogueira Lima JP; Georgieva M; Haaland B; de Lima Lopes G
Cancer Med; 2017 Jun; 6(6):1143-1153. PubMed ID: 28463413
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
29. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
Luke JJ
Oncologist; 2019 Nov; 24(11):e1197-e1211. PubMed ID: 31064886
[TBL] [Abstract][Full Text] [Related]
31. Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.
Maniyar RR; Chakraborty S; Jarboe T; Suriano R; Wallack M; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():123-143. PubMed ID: 34888847
[TBL] [Abstract][Full Text] [Related]
32. The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.
Ascierto PA; Bruzzi P; Eggermont A; Hamid O; Tawbi HA; van Akkooi A; Testori A; Caracò C; Puzanov I; Perrone F
J Transl Med; 2019 May; 17(1):148. PubMed ID: 31077205
[TBL] [Abstract][Full Text] [Related]
33. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in
White MG; Szczepaniak Sloane R; Witt RG; Reuben A; Gaudreau PO; Andrews MC; Feng N; Johnson S; Class CA; Bristow C; Wani K; Hudgens C; Nezi L; Manzo T; De Macedo MP; Hu J; Davis R; Jiang H; Prieto P; Burton E; Hwu P; Tawbi H; Gershenwald J; Lazar AJ; Tetzlaff MT; Overwijk W; Woodman SE; Cooper ZA; Marszalek JR; Davies MA; Heffernan TP; Wargo JA
Oncoimmunology; 2021; 10(1):1992880. PubMed ID: 34777916
[TBL] [Abstract][Full Text] [Related]
34. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
Ascierto PA; Flaherty K; Goff S
Am Soc Clin Oncol Educ Book; 2018 May; 38():751-758. PubMed ID: 30231371
[TBL] [Abstract][Full Text] [Related]
35. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
Ascierto PA; Grimaldi AM; Anderson AC; Bifulco C; Cochran A; Garbe C; Eggermont AM; Faries M; Ferrone S; Gershenwald JE; Gajewski TF; Halaban R; Hodi FS; Kefford R; Kirkwood JM; Larkin J; Leachman S; Maio M; Marais R; Masucci G; Melero I; Palmieri G; Puzanov I; Ribas A; Saenger Y; Schilling B; Seliger B; Stroncek D; Sullivan R; Testori A; Wang E; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2014 Oct; 12():277. PubMed ID: 25348889
[TBL] [Abstract][Full Text] [Related]
36. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Ma W; Gilligan BM; Yuan J; Li T
J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
[TBL] [Abstract][Full Text] [Related]
37. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers for immune therapy in melanoma.
Johnson DB; Chon J; Johnson MR; Balko JM
Semin Cutan Med Surg; 2018 Jun; 37(2):120-126. PubMed ID: 30040089
[TBL] [Abstract][Full Text] [Related]
39. Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates.
Seyhan AA; Carini C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613491
[TBL] [Abstract][Full Text] [Related]
40. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.
Nebhan CA; Johnson DB
Expert Rev Anticancer Ther; 2020 Feb; 20(2):137-145. PubMed ID: 31997676
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
